公开(公告)号：US06184251B2

公开(公告)日：2001-02-06

申请号：US09254074

申请日：2000-02-04

Applicant: Barbara Jacqueline Stordy ,  David F. Horrobin

Inventor： Barbara Jacqueline Stordy ,  David F. Horrobin

IPC: A61K3120

CPC classification number: A61K31/202

Abstract: This invention relates to the administration of arachidonic acid or docosahexaenoic acid or precursors thereof to children or pregnant women for the treatment or prevention of dyspraxia.

Abstract translation: 本发明涉及向儿童或孕妇施用花生四烯酸或二十二碳六烯酸或其前体用于治疗或预防dyspraxia。

公开(公告)号：US5589509A

公开(公告)日：1996-12-31

申请号：US611525

申请日：1996-03-06

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/40 ,  A61K31/42 ,  A61K31/65 ,  A61K47/00 ,  A61P9/10 ,  A61P31/12 ,  A61P35/00

CPC classification number: A61K31/20 ,  A61K31/40 ,  A61K31/65 ,  Y10S514/886

Abstract: A composition comprises a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites), together with a drug that taken alone has a side-effect of sensitizing the skin to light, in particular a porphyrin or tetracycline or Benoxaprofen, alone or in a pharmaceutically acceptable diluent or carrier, the composition reducing that sensitization.

Abstract translation: 组合物包含多不饱和脂肪酸，特别是n-6系列（亚油酸或其代谢物）或n-3系（α-亚麻酸及其代谢物）的必需脂肪酸，以及单独使用的药物 具有使皮肤光敏的副作用，特别是卟啉或四环素或Benoxaprofen，单独或药学上可接受的稀释剂或载体，该组合物降低了该致敏性。

公开(公告)号：US5562913A

公开(公告)日：1996-10-08

申请号：US214553

申请日：1994-03-18

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A23L1/00 ,  A23L1/30 ,  A61K8/36 ,  A61K8/67 ,  A61K9/06 ,  A61K9/12 ,  A61K9/16 ,  A61K31/20 ,  A61Q19/08 ,  A61K7/00 ,  A61K7/06 ,  A61K9/20 ,  A61K9/48

CPC classification number: A61Q19/08 ,  A23L33/12 ,  A61K31/20 ,  A61K8/361 ,  A61K8/67 ,  Y10S424/05 ,  Y10S514/945

Abstract: Preparation of a formulation for mitigating ill effects of smoking, wherein one or more of the n-6 EFAs selected from GLA, DGLA and AA, and one or more of the n-3 EFAs selected from SA, 20:4n-3, EPA, DPA or DHA are used, preferably so that the daily dose of each fatty acid is within the range 1 mg to 100g/day. The formulation may in many other purposes be used in the treatment or prevention of ageing of the skin of smokers.

Abstract translation: 制备用于减轻吸烟不良影响的制剂，其中选自GLA，DGLA和AA的一种或多种n-6FAA和选自SA，20：4n-3，EPA中的一种或多种n-3EFA 优选使用DPA或DHA，使得每种脂肪酸的日剂量在1mg至100g /天的范围内。 该制剂可用于许多其它目的用于治疗或预防吸烟者皮肤老化。

公开(公告)号：US5422115A

公开(公告)日：1995-06-06

申请号：US963597

申请日：1992-10-20

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A01N37/06 ,  A23L1/304 ,  A61K8/19 ,  A61K8/36 ,  A61K8/67 ,  A61K9/28 ,  A61K31/20 ,  A61L15/44 ,  A61Q5/02 ,  A61Q19/00

CPC classification number: A61K8/67 ,  A01N37/06 ,  A23L33/16 ,  A61K31/20 ,  A61K8/19 ,  A61K8/361 ,  A61Q19/00 ,  A61Q5/02 ,  Y10S514/81 ,  Y10S514/821 ,  Y10S514/824 ,  Y10S514/825 ,  Y10S514/866 ,  Y10S514/885 ,  Y10S514/886 ,  Y10S514/905 ,  Y10S514/931 ,  Y10S514/934 ,  Y10S514/943

Abstract: Methods of treatment of the human or animal body are provided to combat conditions responsive to lithium and/or C.sub.18-22 polyunsaturated fatty acid therapy, including conditions associated with essential lithium deficiency, and also transfer of lipid-enveloped viruses between humans or animals or between cells within a human or animal body. The methods include administration of an effective amount of a lithium salt of a C.sub.18-22 polyunsaturated fatty acid. Devices for combatting transmission of viral diseases including lithium salts of a C.sub.18-22 polyunsaturated fatty acid are also provided.

Abstract translation: 提供人体或动物体的治疗方法来对抗对锂和/或C18-22多不饱和脂肪酸治疗的反应条件，包括与必需锂缺乏相关的病症，以及在人或动物之间或之间或之间转移脂质包膜的病毒 人或动物体内的细胞。 所述方法包括施用有效量的C18-22多不饱和脂肪酸的锂盐。 还提供了用于对抗包括C18-22多不饱和脂肪酸的锂盐的病毒性疾病传播的装置。

公开(公告)号：US5328691A

公开(公告)日：1994-07-12

申请号：US891037

申请日：1992-06-01

Applicant: David F. Horrobin ,  Yung-Sheng Huang

Inventor： David F. Horrobin ,  Yung-Sheng Huang

IPC: A61K31/23 ,  A23D9/00 ,  A23L1/30 ,  A61K8/00 ,  A61K8/30 ,  A61K8/37 ,  A61K8/96 ,  A61P13/02 ,  A61P15/00 ,  A61P17/00 ,  A61P25/04 ,  A61Q5/00 ,  A61Q19/00 ,  C07C69/587 ,  C11B3/10 ,  C11B7/00 ,  C11D3/06 ,  A61K31/20 ,  A61K9/14 ,  A61K47/12 ,  A61N37/06

CPC classification number: A23D9/00 ,  A61K31/23 ,  C07C69/587

Abstract: A natural or synthetic glycerol oil which comprises at least 20% by weight, preferably at least 25% of di-linoleoyl-mono-gamma-linolenyl-glycerol (DLMG), is used to supplement foods, nutritional compositions and in skin and hair care compositions.

Abstract translation: 使用包含至少20重量％，优选至少25％的二亚油酰 - 单γ-亚麻油烯甘油（DLMG）的天然或合成甘油油来补充食物，营养组合物和皮肤和头发护理 组合物。

公开(公告)号：US5216142A

公开(公告)日：1993-06-01

申请号：US521075

申请日：1990-04-10

Applicant: David F. Horrobin ,  John C. M. Stewart ,  Michael D. Winther

Inventor： David F. Horrobin ,  John C. M. Stewart ,  Michael D. Winther

IPC: C07D473/18 ,  A61K31/00 ,  A61K31/505 ,  A61K31/52 ,  A61K31/522 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7052 ,  A61K31/7064 ,  A61K31/7072 ,  A61P31/00 ,  A61P31/12 ,  C07D405/04 ,  C07D473/00 ,  C07H19/06 ,  C07H19/073 ,  C07H19/16

CPC classification number: C07D473/00 ,  C07H19/06 ,  C07H19/16

Abstract: Anti-virals wherein a linoleyl, gamma-linolenyl or other unsaturated long chain fatty acyl group is borne directly on a hydroxy or amino group of the sugar/sugar analogue or heterocyclic moiety of a nucleoside or nucleoside analogue.

公开(公告)号：US5080909A

公开(公告)日：1992-01-14

申请号：US429601

申请日：1989-10-31

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A61K31/505 ,  A61K33/14 ,  A61K38/21

CPC classification number: A61K31/70 ,  A61K31/19 ,  A61K31/505 ,  A61K33/14 ,  A61K38/21

Abstract: The anti-viral effectiveness of conventional anti-viral agents such as acyclovir, idoxuridine, vidarabine etc. is enhanced by formulation or administration with a physiologically acceptable lithium salt.

公开(公告)号：US4996233A

公开(公告)日：1991-02-26

申请号：US480375

申请日：1990-02-14

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/40 ,  A61K31/42 ,  A61K31/65 ,  A61K47/00 ,  A61P9/10 ,  A61P31/12 ,  A61P35/00

CPC classification number: A61K31/20 ,  A61K31/40 ,  A61K31/65 ,  Y10S514/886

Abstract: A method of treating the skin sensitizing effects of porphyrins by the systemic administration of an essential polyunsaturated fatty acid of the N-6 or N-3 series or their metabolites.

Abstract translation: 通过全身施用N-6或N-3系列的必需多不饱和脂肪酸或其代谢物来治疗卟啉的皮肤敏化作用的方法。

公开(公告)号：US4977187A

公开(公告)日：1990-12-11

申请号：US359565

申请日：1989-06-01

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/202 ,  A61K31/355 ,  A61P3/06 ,  A61P17/00 ,  A61P25/00 ,  A61P25/18 ,  A61P29/00 ,  A61P37/08

CPC classification number: A61K31/20 ,  A61K31/355

Abstract: Method of, and preparations of medicaments for, treating schizophrenia and/or associated tardive dyskinesia by combining an essential fatty acid selected from GLA and higher N-6 series acids with an essential fatty acid selected from stearidonic acid and higher n-3 series acids in effective daily amounts of 10 mg and 50 g of each acid.

公开(公告)号：US4826877A

公开(公告)日：1989-05-02

申请号：US911794

申请日：1986-09-26

Applicant: Charles Stewart ,  David F. Horrobin ,  Hugh Carmichael

Inventor： Charles Stewart ,  David F. Horrobin ,  Hugh Carmichael

IPC: A61K31/16 ,  A61K31/20 ,  A61K31/202 ,  A61K31/23 ,  A61P3/08 ,  A61P3/10 ,  A61P9/00 ,  A61P13/02 ,  A61P15/00 ,  A61P25/18 ,  A61P27/02 ,  A61K31/22

CPC classification number: A61K31/23 ,  A61K31/16 ,  A61K31/20

Abstract: A method of prevention or treatment of diabetic neuropathy and the other long term complications of diabetes mellitus including complications in the cardovascular system, kidneys and eyes wherein effective amounts of one or both of i) gamma-linolenic acid and/or one or more of the metabolites of gamma-linolenic acid (DGLA, AA, 22:4 n-6 or 22:5 n-6) and ii) 18:4 n-3 and/or one or more of the metabolites of 18:4 n-3 (20:4 n-3, 20:5 n-3, 22:5 n-3, 22:6 n-3) are administered against such complications as such or in the form of an ester, salt, amide or other derivative convertible in the body thereto, alone or in an acceptable pharmaceutical carrier or diluent.

Abstract translation: 一种预防或治疗糖尿病性神经病和糖尿病的其它长期并发症的方法，包括心血管系统，肾脏和眼睛中的并发症，其中有效量的i）γ-亚麻酸和/或一种或多种 γ-亚麻酸的代谢物（DGLA，AA，22：4 n-6或22：5 n-6）和ii）18：4 n-3和/或18：4 n-3的一种或多种代谢物 （20：4 n-3,20：5 n-3,22：5 n-3,22：6 n-3）针对此类并发症或酯，盐，酰胺或其他衍生物的形式施用 在体内可单独或在可接受的药物载体或稀释剂中转化。